Oligonucleotide therapeutics

siRNA
#Financing #Oligonucleotide therapeutics #Ractigen Therapeutics #RNA #RNA Therapeutics #saRNA

Ractigen Therapeutics closes over $31 million financing 

Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, has closed a new financing round exceeding $31 million (over RMB 200 million).  The round was led by Guozhong Capital, with participation from IDG Capital, China Everbright Limited, Jolmo Capital, Win-Win Capital, and SND Financial… Read More

#News